16129840

Source:http://linkedlifedata.com/resource/pubmed/id/16129840

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0002073, umls-concept:C0012634, umls-concept:C0026764, umls-concept:C0035020, umls-concept:C0205210, umls-concept:C0439831, umls-concept:C0683598, umls-concept:C1274040, umls-concept:C1880022
pubmed:issue	28
pubmed:dateCreated	2005-9-29
pubmed:abstractText	To determine whether primary drug resistance or rapid relapse explains the poor prognosis seen in t(4;14)-positive multiple myeloma (MM).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating, http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin A, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	0732-183X
pubmed:author	pubmed-author:AspD SDS, pubmed-author:ChangHongH, pubmed-author:ChenChristineC, pubmed-author:JaksicWilfridW, pubmed-author:MikhaelJosephJ, pubmed-author:ReeceDonnaD, pubmed-author:StewartA KeithAK, pubmed-author:TrieuYoungY, pubmed-author:TrudelSuzanneS
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	23
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	7069-73
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:16129840-Adult, pubmed-meshheading:16129840-Aged, pubmed-meshheading:16129840-Antineoplastic Agents, Alkylating, pubmed-meshheading:16129840-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16129840-Chromosomes, Human, Pair 14, pubmed-meshheading:16129840-Chromosomes, Human, Pair 4, pubmed-meshheading:16129840-Dexamethasone, pubmed-meshheading:16129840-Disease Progression, pubmed-meshheading:16129840-Doxorubicin, pubmed-meshheading:16129840-Drug Resistance, Neoplasm, pubmed-meshheading:16129840-Female, pubmed-meshheading:16129840-Follow-Up Studies, pubmed-meshheading:16129840-Humans, pubmed-meshheading:16129840-Immunoglobulin A, pubmed-meshheading:16129840-In Situ Hybridization, Fluorescence, pubmed-meshheading:16129840-Male, pubmed-meshheading:16129840-Middle Aged, pubmed-meshheading:16129840-Multiple Myeloma, pubmed-meshheading:16129840-Prognosis, pubmed-meshheading:16129840-Recurrence, pubmed-meshheading:16129840-Salvage Therapy, pubmed-meshheading:16129840-Survival Analysis, pubmed-meshheading:16129840-Time Factors, pubmed-meshheading:16129840-Translocation, Genetic, pubmed-meshheading:16129840-Vincristine
pubmed:year	2005
pubmed:articleTitle	Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
pubmed:affiliation	Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Canada.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't